Form: SC 13G

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

September 2, 2014

Exhibit 1
 
JOINT FILING AGREEMENT
 
This Joint Filing Agreement, dated as of September 2, 2014, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LLC and Bihua Chen (collectively, the "Filers").
 
Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Shares of Cellectar Biosciences, Inc. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

 
 
CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
By: Cormorant Global Healthcare GP, LLC
       its General Partner
 
       
 
By:
/s/ Bihua Chen  
    Name: Bihua Chen   
    Title:  Managing Member   
       
 
  CORMORANT GLOBAL HEALTHCARE GP, LLC  
       
 
By:
/s/ Bihua Chen  
    Name: Bihua Chen  
    Title:  Managing Member   
       
 
  CORMORANT ASSET MANAGEMENT, LLC  
       
 
By:
/s/ Bihua Chen  
    Name: Bihua Chen  
    Title:  Managing Member   
       

     
       
 
By:
/s/ Bihua Chen  
    Bihua Chen